Dataset Information

Hemostatic and platelet proteins associate with bleeding grade and time-to-major bleed in hemato-oncological patients

ABSTRACT: Bleeding crises are common complications in hemato-oncological patients undergoing chemotherapy and stem cell transplantation. Platelet transfusions are frequently administered to treat and prevent bleeding events at low platelet counts. However, the association between thrombocytopenia and bleeding events remains unclear, arguing for an improved understanding of pathophysiological changes underpinning bleeding events. Therefore, this study aims to identify plasma protein levels associated with bleeding events in a hemato-oncological patient population using unbiased mass spectrometry-based plasma profiling. Plasma samples and clinical records from 176 hemato-oncological patients included in the Pathogen Reduction Evaluation & Predictive Analytical Rating Score (PREPAReS) study were analyzed. Out of 600 identified proteins, abundance levels of 55 proteins were found to be associated with bleeding severity at time of sampling. Among these, a large cluster of platelet proteins (n = 48) as well as coagulation factor 7 (F7) and vitamin-K dependent protein C (PROC) were observed. Interestingly, nine out of these 55 proteins were also associated with time-to-major bleeding event (WHO grade 2 or higher). Platelet protein levels correlated with platelet counts, but not with white cell counts nor platelet transfusions. Taken together, our results suggest that lower abundance of platelet- and coagulation proteins in plasma are associated with increased bleeding grade and time-to-major bleeding events in hemato-oncological patients. This highlights the potential for improved hemostatic monitoring of hemato-oncological patients at risk of bleeding, beyond platelet count alone.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

DISEASE(S): Hematologic Cancer

SUBMITTER: Eva Smit

LAB HEAD: Maartje van den Biggelaar

PROVIDER: PXD071376 | Pride | 2026-03-31

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	0234_DR_S1-H12_1_12976.d.ZIP	Other
	100_2012-11-27_S5-D9_5590.d.ZIP	Other
	100_2012-11-30_S5-D8_5589.d.ZIP	Other
	100_2012-12-05_S5-D12_5593.d.ZIP	Other
	100_2012-12-07_S5-D11_5592.d.ZIP	Other

Items per page:

1 - 5 of 689

Similar Datasets

Project description:Rationale: Peripheral arterial disease (PAD) is associated with a high risk of cardiovascular events and death and is postulated to be a critical socioeconomic cost in the future. Extracellular vesicles (EVs) have emerged as potential candidates for new biomarker discovery related to their protein and nucleic acid cargo. Objective: To study prothrombotic activity, cellular origin and transcriptomic profile of circulating EVs and to assess them as prognostic and therapeutic targets in PAD. Methods and Results: This prospective study included control and PAD patients. Coagulation time (Procoag-PPL kit), EVs cellular origin and phosphatidylserine exposure were determined by flow cytometry in platelet-free plasma (n=45 PAD). Transcriptomic profiles of medium/large EVs were generated using the MARS-Seq RNA-Seq protocol (n=12/group). The serum concentration of the differentially expressed gene calprotectin was validated by ELISA in control (n=100) and PAD patients (n=317). Calprotectin was also determined in EVs and tissues of human atherosclerotic plaques (n=3). Circulating EVs of PAD patients were mainly of platelet origin, predominantly AnnexinV positive and were associated with the procoagulant activity of platelet-free plasma. Transcriptomic analysis of EVs identified 15 differentially expressed genes. Among them, serum calprotectin was elevated in PAD patients (p<0.05) and associated with increased amputation risk before and after covariate adjustment (mean follow-up 3.6 years, p<0.01). The combination of calprotectin with hs-CRP in the multivariate analysis further improved risk stratification (p<0.01). Furthermore, calprotectin was also expressed in femoral plaque derived EVs and tissues. Conclusions: We found that PAD patients release EVs, mainly of platelet origin, highly positive for AnnexinV and rich in transcripts related to platelet biology and immune responses. Amputation risk prediction improved with calprotectin and was significantly higher when combined with hs-CRP. Our results suggest that EVs can be a promising component of liquid biopsy with prognostic implications in PAD.

Dataset Information

Hemostatic and platelet proteins associate with bleeding grade and time-to-major bleed in hemato-oncological patients

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets